1,272 Amgen Inc. $AMGN Shares Purchased by Venture Visionary Partners LLC

Venture Visionary Partners LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 3.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,030 shares of the medical research company’s stock after buying an additional 1,272 shares during the quarter. Venture Visionary Partners LLC’s holdings in Amgen were worth $18,559,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. MW Advisory LLC bought a new stake in shares of Amgen in the second quarter valued at about $1,054,000. Baird Financial Group Inc. raised its stake in Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after acquiring an additional 5,496 shares in the last quarter. Integrated Advisors Network LLC grew its stake in Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company’s stock worth $6,664,000 after buying an additional 6,356 shares during the last quarter. KBC Group NV boosted its holdings in shares of Amgen by 51.7% in the 2nd quarter. KBC Group NV now owns 382,676 shares of the medical research company’s stock worth $138,574,000 after acquiring an additional 130,497 shares in the last quarter. Finally, Nilsine Partners LLC bought a new stake in shares of Amgen during the second quarter worth $3,329,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN traded up $10.48 during mid-day trading on Wednesday, hitting $413.08. 2,236,544 shares of the stock were exchanged, compared to its average volume of 2,758,837. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock has a market capitalization of $223.32 billion, a price-to-earnings ratio of 25.67, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03. The firm’s 50-day simple moving average is $411.95 and its 200 day simple moving average is $371.46.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on AMGN shares. Cantor Fitzgerald reissued a “neutral” rating on shares of Amgen in a report on Monday. Truist Financial upped their target price on shares of Amgen from $362.00 to $380.00 and gave the company a “hold” rating in a research note on Wednesday. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating and set a $450.00 price objective on the stock. in a report on Tuesday, September 8th. Jefferies Financial Group reaffirmed a “hold” rating and set a $410.00 price objective on shares of Amgen in a research report on Wednesday, September 23rd. Finally, Canaccord Genuity Group lifted their price target on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $385.79.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported results from a clinical trial involving a treatment for Sjögren’s disease. The update appears to have supported the stock by providing investors with additional visibility into the company’s immunology pipeline. Amgen announces Sjogren’s trial results
• Positive Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing. The investment could give Amgen access to AI-driven genetic testing and molecular-data capabilities that may improve precision-medicine decisions and the design of genomically targeted clinical trials. Amgen backs Arboretum LifeSciences Series A
• Positive Sentiment: Amgen’s AMG 513 obesity study reached Phase 1 completion. While early-stage completion does not establish efficacy, the program adds another potential growth opportunity as the company competes in the weight-loss drug market. Amgen AMG 513 obesity trial update
• Neutral Sentiment: Cantor Fitzgerald maintained a Neutral rating, while another report cited a Neutral rating with a $400 price target. These views suggest analysts see limited near-term upside after the recent advance. Cantor Fitzgerald maintains Neutral rating
• Neutral Sentiment: A former Amgen commercial leader joined Entera Bio, a move relevant to Entera rather than Amgen and unlikely to materially affect AMGN’s fundamentals. Former Amgen leader joins Entera
• Negative Sentiment: Morgan Stanley lowered its price target to $359 while maintaining an Equal Weight rating, and Truist raised its target to $380 but kept a Hold rating. Both targets remain below the current share price, signaling valuation concerns and potential downside. Morgan Stanley lowers Amgen price target Truist raises Amgen price target

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.